These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17536027)

  • 1. Systemic inflammation and progression of COPD.
    Vestbo J
    Thorax; 2007 Jun; 62(6):469-70. PubMed ID: 17536027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small airways in COPD.
    Barnes PJ
    N Engl J Med; 2004 Jun; 350(26):2635-7. PubMed ID: 15215476
    [No Abstract]   [Full Text] [Related]  

  • 3. Eosinophilic airway inflammation in chronic obstructive pulmonary disease and asthma.
    Gorska K; Krenke R; Korczynski P; Kosciuch J; Domagala-Kulawik J; Chazan R
    J Physiol Pharmacol; 2008 Dec; 59 Suppl 6():261-70. PubMed ID: 19218650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease.
    Valipour A; Schreder M; Wolzt M; Saliba S; Kapiotis S; Eickhoff P; Burghuber OC
    Clin Sci (Lond); 2008 Oct; 115(7):225-32. PubMed ID: 18307413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic inflammation in COPD visualised by gene profiling in peripheral blood neutrophils.
    Oudijk EJ; Nijhuis EH; Zwank MD; van de Graaf EA; Mager HJ; Coffer PJ; Lammers JW; Koenderman L
    Thorax; 2005 Jul; 60(7):538-44. PubMed ID: 15994259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study.
    Kunisaki KM; Rice KL; Janoff EN; Rector TS; Niewoehner DE
    Ther Adv Respir Dis; 2008 Apr; 2(2):55-64. PubMed ID: 19124359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression.
    Brajer B; Batura-Gabryel H; Nowicka A; Kuznar-Kaminska B; Szczepanik A
    J Physiol Pharmacol; 2008 Dec; 59 Suppl 6():145-52. PubMed ID: 19218638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New pharmacological options in the therapy of COPD].
    Watz H; Kanniess F; Magnussen H
    Pneumologie; 2007 Jun; 61(6):365-73. PubMed ID: 17492578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nasal symptoms, airway obstruction and disease severity in chronic obstructive pulmonary disease.
    Hurst JR; Kuchai R; Michael P; Perera WR; Wilkinson TM; Wedzicha JA
    Clin Physiol Funct Imaging; 2006 Jul; 26(4):251-6. PubMed ID: 16836700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [More research is needed to understand the airway inflammation in chronic obstructive pulmonary disease].
    He P
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2089-91. PubMed ID: 19080465
    [No Abstract]   [Full Text] [Related]  

  • 11. Longitudinal follow-up of systemic inflammation after acute exacerbations of COPD.
    Groenewegen KH; Dentener MA; Wouters EF
    Respir Med; 2007 Nov; 101(11):2409-15. PubMed ID: 17644367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal muscle weakness, reduced exercise tolerance, and COPD: is systemic inflammation the missing link?
    Sin DD; Man SF
    Thorax; 2006 Jan; 61(1):1-3. PubMed ID: 16396949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic obstructive pulmonary disease: beyond the forced expiratory manoeuvre.
    Agustí A
    Respiration; 2008; 75(2):136-7. PubMed ID: 18332621
    [No Abstract]   [Full Text] [Related]  

  • 14. The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression.
    Wise RA
    Am J Med; 2006 Oct; 119(10 Suppl 1):4-11. PubMed ID: 16996894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inspiratory capacity and forced expiratory volume in the first second in exacerbation of chronic obstructive pulmonary disease.
    Yetkin O; Gunen H
    Clin Respir J; 2008 Jan; 2(1):36-40. PubMed ID: 20298302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting development and progression of COPD.
    Quanjer PH; Steenbruggen I; Ruppel G; Swanney MP
    Thorax; 2008 Nov; 63(11):1027-8; author reply 1028. PubMed ID: 18984822
    [No Abstract]   [Full Text] [Related]  

  • 17. Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease.
    Broekhuizen R; Wouters EF; Creutzberg EC; Weling-Scheepers CA; Schols AM
    Thorax; 2005 May; 60(5):376-82. PubMed ID: 15860712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of priming-associated cellular markers on neutrophils during an exacerbation of COPD.
    Oudijk EJ; Gerritsen WB; Nijhuis EH; Kanters D; Maesen BL; Lammers JW; Koenderman L
    Respir Med; 2006 Oct; 100(10):1791-9. PubMed ID: 16531033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease.
    Karadag F; Kirdar S; Karul AB; Ceylan E
    Eur J Intern Med; 2008 Mar; 19(2):104-8. PubMed ID: 18249305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease.
    van Eeden SF; Sin DD
    Respiration; 2008; 75(2):224-38. PubMed ID: 18042978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.